Parvus Therapeutics enters global collaboration and licensing agreement with Genentech to develop Navacim ™ Therapeutics for the treatment of autoimmune diseases
[ad_1] BURLINGAME, Calif. And CALGARY, Alberta – (COMMERCIAL THREAD) – Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory drugs to treat autoimmune diseases without altering normal immunity, has entered into a global collaboration and licensing agreement with group member Genentech Roche, to develop, manufacture and market novel Navacim â„¢ therapeutic products […]